Global Duchenne Muscular Dystrophy Market Insights, Epidemiology and Market Forecasts, 2017-2020 & 2030 - ResearchAndMarkets.com

DUBLIN--()--The "Duchenne Muscular Dystrophy- Market Insight, Epidemiology and Market Forecast -2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Duchenne Muscular Dystrophy (DMD) -Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the Duchenne Muscular Dystrophy (DMD), historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy (DMD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Duchenne Muscular Dystrophy (DMD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Duchenne Muscular Dystrophy (DMD) market size from 2017 to 2030. The report also covers current Duchenne Muscular Dystrophy (DMD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Duchenne Muscular Dystrophy (DMD) Epidemiology

Key Findings

This section provides glimpse of the Duchenne Muscular Dystrophy (DMD) epidemiology in the 7MM.

  • The total diagnosed prevalent population of Duchenne Muscular Dystrophy (DMD) in the seven major markets was found to be 27,685 in 2017. In case of DMD patients in the United States, the diagnosed prevalent cases were 16,840 in 2017.
  • The total diagnosed prevalent cases of Duchenne Muscular Dystrophy (DMD) patients were found to be maximum in the age-group 8-13 year and 14-19 year in the United States, which was 4,757 and 4,714 respectively in 2017.
  • In EU5 countries the diagnosed prevalence was found to be 27,685 in 2017, which is expected to rise in the forecast period 2020-2030.

Market Insights:

  • What was the Duchenne Muscular Dystrophy (DMD) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Duchenne Muscular Dystrophy (DMD) total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Duchenne Muscular Dystrophy (DMD) market size during the forecast period (2020-2030)?
  • At what CAGR, the Duchenne Muscular Dystrophy (DMD) market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the Duchenne Muscular Dystrophy (DMD) market outlook across the 7MM during the forecast period (2020-2030)?
  • What would be the Duchenne Muscular Dystrophy (DMD) market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Duchenne Muscular Dystrophy (DMD)?
  • What is the historical Duchenne Muscular Dystrophy (DMD) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Duchenne Muscular Dystrophy (DMD) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Duchenne Muscular Dystrophy (DMD)?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Duchenne Muscular Dystrophy (DMD) during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Duchenne Muscular Dystrophy (DMD) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Duchenne Muscular Dystrophy (DMD) in the US and Europe?
  • What are the Duchenne Muscular Dystrophy (DMD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Duchenne Muscular Dystrophy (DMD)?
  • How many therapies are developed by each company for the treatment of Duchenne Muscular Dystrophy (DMD)?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Duchenne Muscular Dystrophy (DMD)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Duchenne Muscular Dystrophy (DMD) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Duchenne Muscular Dystrophy (DMD) and their status?
  • What are the key designations that have been granted for the emerging therapies for Duchenne Muscular Dystrophy (DMD)?
  • What are the 7MM historical and forecasted market of Duchenne Muscular Dystrophy (DMD)?

Companies Mentioned

  • Sarepta Therapeutics
  • PTC Therapeutics
  • Italfarmaco
  • Catabasis Pharmaceuticals
  • Nippon Shinyaku (NS Pharma)
  • Pfizer
  • Santhera Pharmaceuticals/ReveraGen BioPharma
  • Taiho Pharmaceutical
  • FibroGen
  • Capricor
  • Daiichi Sankyo

Marketed Drugs

  • Vyondys 53 (Golodirsen): Sarepta Therapeutics
  • Emflaza: PTC Therapeutics
  • Exondys 51: Sarepta Therapeutics
  • Translarna: PTC Therapeutics

Emerging Drugs: Key Cross Competition

  • Casimersen: Sarepta Therapeutics
  • Puldysa (Idebenone): Santhera Pharmaceuticals
  • Givinostat: Italfarmaco
  • Edasalonexent: Catabasis Pharmaceuticals
  • Viltolarsen: Nippon Shinyaku (NS Pharma)
  • PF-06939926: Pfizer
  • Vamorolone: Santhera Pharmaceuticals/ReveraGen BioPharma
  • TAS-205: Taiho Pharmaceutical
  • Pamrevlumab (FG-3019): FibroGen
  • SRP-9001: Sarepta Therapeutics
  • Allogeneic Cardiosphere-Derived Cells (CAP-1002): Capricor
  • DS-5141b: Daiichi Sankyo

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/c4vq59

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900